A director at Fisher & Paykel Healthcare Corporation Limited bought 1,000 shares at 32.300AUD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
The independent financial analyst theScreener just lowered the general evaluation of FISHER&PAYKEL HEALTH (NZ), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 14, 2022, the closing price was ...
The independent financial analyst theScreener just lowered the general evaluation of FISHER&PAYKEL HEALTH (AU), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date January 11, 2022, the closing price was AUD 29.92 and its...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Despite many Australian-listed healthcare stocks we cover having substantial revenue exposure to the U.S., the latest potential regulatory changes in that market pose a low risk to our fair value estimates. The cost of and access to healthcare is an emotive topic among U.S. voters and hence at the forefront of political agendas. Of relevance to the Australian companies that operate in the U.S. is the draft Lower Health Care Costs Act, or LHCCA, which aims to improve transparency in the healthcar...
Despite many Australian-listed healthcare stocks we cover having substantial revenue exposure to the U.S., the latest potential regulatory changes in that market pose a low risk to our fair value estimates. The cost of and access to healthcare is an emotive topic among U.S. voters and hence at the forefront of political agendas. Of relevance to the Australian companies that operate in the U.S. is the draft Lower Health Care Costs Act, or LHCCA, which aims to improve transparency in the healthcar...
Despite many Australian-listed healthcare stocks we cover having substantial revenue exposure to the U.S., the latest potential regulatory changes in that market pose a low risk to our fair value estimates. The cost of and access to healthcare is an emotive topic among U.S. voters and hence at the forefront of political agendas. Of relevance to the Australian companies who operate in the U.S. is the draft Lower Health Care Costs Act, or LHCCA, which aims to improve transparency in the healthcare...
Despite many Australian-listed healthcare stocks we cover having substantial revenue exposure to the U.S., the latest potential regulatory changes in that market pose a low risk to our fair value estimates. The cost of and access to healthcare is an emotive topic among U.S. voters and hence at the forefront of political agendas. Of relevance to the Australian companies who operate in the U.S. is the draft Lower Health Care Costs Act, or LHCCA, which aims to improve transparency in the healthcare...
The transition of coverage to a new analyst and reduction in cost of equity following a review of narrow-moat Fisher & Paykel’s systemic risk exposure has us raising our fair value estimate to NZD 16.40 from NZD 11.00, despite weaker than expected growth reported and a subdued outlook in the homecare division. Based on an AUD/NZD exchange rate of 1.05, our fair value estimate is revised to AUD 15.60 up from AUD 10.70. Fisher & Paykel reported constant currency revenue growth of 8%, well short...
The transition of coverage to a new analyst and reduction in cost of equity following a review of narrow-moat Fisher & Paykel’s systemic risk exposure has us raising our fair value estimate to NZD 16.40 from NZD 11.00, despite weaker than expected growth reported and a subdued outlook in the homecare division. Based on an AUD/NZD exchange rate of 1.05, our fair value estimate is revised to AUD 15.60 up from AUD 10.70. Fisher & Paykel reported constant currency revenue growth of 8%, well short...
Fisher & Paykel enjoys a long growth trajectory as both the hospital and homecare markets for respiratory devices are growing strongly. Application of their high flow nasal therapy is the main driver of growth and is gaining clinical traction in the hospital market where Fisher & Paykel have an established stronghold. The market for this and other new applications has grown at a five-year CAGR of 24.2% and we forecast a forward growth rate of 20%. The use of Fisher & Paykel product in producing ...
Fisher & Paykel enjoys a long growth trajectory as both the hospital and homecare markets for respiratory devices are growing strongly. Application of their high flow nasal therapy is the main driver of growth and is gaining clinical traction in the hospital market where Fisher & Paykel have an established stronghold. The market for this and other new applications has grown at a five-year CAGR of 24.2% and we forecast a forward growth rate of 20%. The use of Fisher & Paykel product in producing ...
The transition of coverage to a new analyst and reduction in cost of equity following a review of narrow-moat Fisher & Paykel’s systemic risk exposure has us raising our fair value estimate to NZD 16.40 from NZD 11.00, despite weaker than expected growth reported and a subdued outlook in the homecare division. Based on an AUD/NZD exchange rate of 1.05, our fair value estimate is revised to AUD 15.60 up from AUD 10.70. Fisher & Paykel reported constant currency revenue growth of 8%, well ...
The transition of coverage to a new analyst and reduction in cost of equity following a review of narrow-moat Fisher & Paykel’s systemic risk exposure has us raising our fair value estimate to NZD 16.40 from NZD 11.00, despite weaker than expected growth reported and a subdued outlook in the homecare division. Based on an AUD/NZD exchange rate of 1.05, our fair value estimate is revised to AUD 15.60 up from AUD 10.70. Fisher & Paykel reported constant currency revenue growth of 8%, well ...
We make no changes to our NZD 11.00 per share fair value estimate for narrow-moat-rated Fisher & Paykel Healthcare, and continue to rate the firm as overvalued. Our fiscal 2019 net profit after tax forecast of NZD 210 million stands and is at the top end of management's NZD 205-210 million guidance. However, we increase our fair value estimate for the Australian CDIs to AUD 10.70, due solely to the appreciation of the New Zealand dollar against the Australian dollar with the exchange rate cu...
We make no changes to our NZD 11.00 per share fair value estimate for narrow-moat-rated Fisher & Paykel Healthcare, and continue to rate the firm as overvalued. Our fiscal 2019 net profit after tax forecast of NZD 210 million stands and is at the top end of management's NZD 205-210 million guidance. However, we increase our fair value estimate for the Australian CDIs to AUD 10.70, due solely to the appreciation of the New Zealand dollar against the Australian dollar with the exchange rate cu...
We make no changes to our NZD 11.00 per share fair value estimate for narrow-moat-rated Fisher & Paykel Healthcare, and continue to rate the firm as overvalued. Our fiscal 2019 net profit after tax forecast of NZD 210 million stands and is at the top end of management's NZD 205-210 million guidance. However, we increase our fair value estimate for the Australian CDIs to AUD 10.70, due solely to the appreciation of the New Zealand dollar against the Australian dollar with the exchange rate curren...
We make no changes to our NZD 11.00 per share fair value estimate for narrow-moat-rated Fisher & Paykel Healthcare, and continue to rate the firm as overvalued. Our fiscal 2019 net profit after tax forecast of NZD 210 million stands and is at the top end of management's NZD 205-210 million guidance. However, we increase our fair value estimate for the Australian CDIs to AUD 10.70, due solely to the appreciation of the New Zealand dollar against the Australian dollar with the exchange rate curren...
Fisher & Paykel Healthcare's treatments for respiratory and acute care (through its hospital division) and obstructive sleep apnoea (as part of its homecare business) possess solid growth prospects. We estimate the overall market opportunity at close to 130 million patients, split equally between the two segments, with an estimated 20 million-25 million patients currently undergoing treatment for these disorders. Hospital in particular enjoys strong competitive advantages because of the dominant...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.